drugset
Drugs / Activated T lymphocytes
last change May 2022 re-read 3 minutes ago

Activated T lymphocytes

also known as ATL
Developed for
hepatocellular carcinoma
Investigated by
Lukas Biomedical Inc. · Virginia Contract Research Organization Co., Ltd.

Trials 1

today NCT05304481 · Ph 2
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05304481 May 2022 → Dec 2026 expected hepatocellular carcinoma Lukas Biomedical Inc. Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Activated T lymphocytes “Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma” NCT05304481 ↗
Known as ATL ClinicalTrials.gov intervention name — accepted as the source's own label NCT05304481 ↗
Route Intravenous “Subjects have ATL administration using intravenous infusion” NCT05304481 ↗